Cannabinoid hyperemesis syndrome presenting with ventricular bigeminy | Journal of Cannabis Research
The patient’s description of his “gastritis” is typical of CHS, with severe nausea and cyclical vomiting that resolves after cannabis cessation in a person using cannabis for many years, as supported by the Sontineni and Rome IV criteria (Sontineni et al. 2009; Stanghellini et al. 2016; Venkatesan et al. 2020). Specifically, the patient’s symptoms had been present for more than 6 months and consisted of stereotypical episodic vomiting resembling cyclic vomiting syndrome in terms of onset, duration, and frequency. These occurred after prolonged use of cannabis, and when he stopped cannabis, the vomiting would subside.
Because the symptoms of CHS present closely to that of cyclic vomiting syndromes, the diagnosis can be delayed. This delay in diagnosis can also be partially attributed to the social stigma surrounding cannabis use. In this case, the patient was very upfront about their frequent cannabis and alcohol use, which was critical information in reaching this diagnosis. However, the patient’s recurrent gastritis was dismissed multiple times and not seriously considered as a possible symptom of CHS. This is likely because the typical chief complaint associated with this syndrome is nausea or vomiting. It is important to note that esophagogastroduodenoscopy findings from several patients with CHS have revealed varying grades of esophagitis and gastritis (Galli et al. 2011). As cannabis and cannabis products become more widely used, it is imperative that clinicians familiarize themselves with evidence that shows the paradoxical effects that it has on the gastrointestinal tract (Habboushe et al. 2018). Although in small doses cannabis can actually be an anti-emetic, overuse and using higher doses can result in CHS. Sometimes, patients will take more at the first sign of nausea, because of this. Knowing a patient’s drug history helps clinicians more quickly arrive at the diagnosis.
The cannabinoid receptor type 1 (CB1) receptors stimulated by cannabis are key in the pathophysiology and treatment of CHS. These receptors are present in both the central nervous system (CNS) and the enteric plexus and are responsible for cannabis’s neurologic and gastrointestinal effects (Patterson et al. 2010; Hickey et al. 2013). Although cannabis has been utilized for the treatment of nausea, chronic or significant cannabinoid use can produce the paradoxical effects of cyclic vomiting as seen in CHS (Patterson et al. 2010). One possible explanation is that CB1 receptor stimulation has been shown to slow gastric emptying and inhibit peristalsis, which may play a role in the pathogenesis of CHS (Chang and Windish 2009). Additionally, the presence of these receptors near the thermoregulatory center of the hypothalamus may explain the association of warm bathing with relief in symptoms (Patterson et al. 2010; Pierard and Hantson 2017). Typical acute treatment regimens have included intravenous fluid hydration, antiemetics, and benzodiazepines. However, when these approaches fail, the dopamine D2 receptor blocker, haloperidol, has been utilized—as in our patient. (Venkatesan et al. 2020). The effectiveness of haloperidol in CHS may be explained by the association of D2 receptors in the chemoreceptor trigger zone associated with emesis and the role of haloperidol in interfering with the known complex interactions between dopamine and CB1 signaling mechanisms (Hickey et al. 2013; Witsil and Mycyk 2017).
The patient also presents with ventricular bigeminy, which occurs when the heart alternates between a normal sinus rhythm and a premature ventricular complex (PVC). PVCs are often associated with structural heart disease and increase the risk of sudden death in people with this condition (Ahn 2013). The magnitude of the mortality risk depends on the severity of the underlying disease. Risk factors for PVCs include underlying ischemic heart disease, advanced age, male gender, hypertension, hypomagnesaemia, hypokalemia, and bundle branch block (Farzam 2021). The patient did not present with any of these risk factors. In the absence of heart disease, PVCs carry no adverse prognostic significance if the individual is under the age of 30 (considered to be benign), as seen in this case (Ahn 2013). Although there are no established links/causal relationship between ventricular bigeminy and CHS, cannabis use has been reported to trigger coronary vasospasm, which can result in ischemic ECG changes resembling acute coronary syndromes (Pierard and Hantson 2017).
A literature search of [cannabinoid hyperemesis syndrome] OR [cannabis] AND [ventricular bigeminy] OR [bigeminy] conducted in December 2021 did not identify any studies. The search covered PubMed and Embase, included years 2000–2022, and was limited to articles in English. Since then, there has been one case report that reported on the association of cannabis with myocardial infraction (Aissaoui et al. 2022) and one study that examined the association of self-reported cannabis use with cardiac arrhythmias (Harding et al. 2022). The cardiac arrhythmias noted in the latter included supraventricular tachycardias and PVCs. Premature ventricular contractions can be a precursor to ventricular bigeminy.
While it may seem counterintuitive to give haloperidol for ventricular bigeminy, a phase IV trial of 21,383 people who took haloperidol revealed that only 1 person (0.0%) experienced bigeminy (Haldol and Ventricular 2023).
How cannabis can produce ventricular bigeminy can perhaps be explained by the presence of CB1 receptors in the myocardium. Their activation may result in increased generation of reactive oxygen species that predispose vasospastic responses (Patterson et al. 2010). In addition, the well-known increased sympathetic nervous system activity from cannabis may also result in myocardial changes. These effects on the myocardium mirror the association of PVCs with structural heart disease and may be key in explaining the ventricular bigeminy seen in our patient (Patterson et al. 2010).
It is possible that ventricular bigeminy is associated with cannabis use, rather than CHS per se. To the authors’ knowledge, bigeminy is not associated with other vomiting disorders. Dehydration and electrolyte imbalances may also contribute to bigeminy, but our patient did not display any overt signs of these pathologies.
